Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAQUALITY: Infliximab in Moderate-to-Severe Psoriasis
NCT00687401Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in psoriasis, sponsored by Merck & Co.. Started Jun 2006; status: completed.
02
Drugs
infliximab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00687401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687401.